Last edition
News about "Eylea"
China Accepts Bayer's Aflibercept 8 mg Application for RVO Macular Edema Review
China’s National Medical Products Administration (NMPA) accepts aflibercept 8 mg for review in RVO-related macular edema, supported by positive Phase 3 QUASAR results.
Eylea | 14/08/2026 | By News Bureau | 104
Biocon Announces US Commercial Launch of Yesafili, a Biosimilar to Regeneron's Eylea 2 mg
Biocon has launched Yesafili, an interchangeable biosimilar to Eylea 2 mg in the US, expanding access to treatment for Age-related Macular Degeneration (AMD) and other retinal diseases.
Eylea | 03/08/2026 | By News Bureau
Alvotech and Advanz Pharma Secure European Approval for Eylea Biosimilar Mynzepli
Alvotech and its commercial partner Advanz Pharma have announced that the European Commission has granted marketing authorisation for Mynzepli (aflibercept), a biosimilar to Eylea, available in both pre-filled syringes and vials.
Eylea | 22/08/2025 | By Dineshwori | 252
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy